Advertisement

Topics

Latest Biological Patent NewsRSS

01:54 EDT 23rd September 2017 | BioPortfolio

Indivior to appeal US ruling on opioid addiction patent

UK-based addiction treatment manufacturer Indivior Plc have announced plans to appeal against a US court, which ruled that Indian generics manufacturer Dr Reddy’s Laboratories (Dr Reddy’s) had not infringed patents on their opioid addiction treatment Suboxone.

Hollywog LLC Issued US Patent Covering Mobile Device Control of a TENS Therapy Unit

CHATTANOOGA, Tenn., Sept. 21, 2017 /PRNewswire/ -- Hollywog LLC, a consumer-focused medical device company in Tennessee that creates innovative solutions for a pain-free and healthy life, is pleased to announce the US Patent and Trademark Office has just awarded an important new patent that will advance the field of pain relief entitled "Portable TENS Apparatus and Method of Use Thereof." The pate...

Orthocell Receives New Patent For Celgro Platform Technology

  Life Sciences Jobs   ...

diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 5, 2011 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today said that it plans to present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disord...

USPTO Confirms Patentability of U.S. Patent No. 9,180,140 Exclusively Licensed by ThermoLife International

LOS ANGELES, Sept. 20, 2017 /PRNewswire/ -- ThermoLife International, LLC announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Intent to Issue Ex Parte Reexamination Certificates for Patent No. 9,180,140, which is exclusively licensed by ThermoLife from HeartBeet Ltd.  The Patent's claims generally pertain to reducing oxygen consumption and enhanci...

SpinalCyte, LLC Announces New Australian Patent

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2015202319, “Methods And Compositions For Repair of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent invol...

Meet Dr. Terri Shieh-Newton, life sciences patent attorney

The post Meet Dr. Terri Shieh-Newton, life sciences patent attorney appeared first on SynBioBeta.

Early Draft - Corcept Mouse Studies - Combination Therapy - CORT125134 & CORT125281 + Checkpoint Inhibitors

While I usually don't release unfinished drafts to the public, I promised a sneak peek to the Investor Village community. This draft will be extended and finished over the next day. Come back and see the finished product. I think you'll apreciate the additional color. On September 10, 2017, we wroteabout the new checkpoint inhibitor study from the University of Chicago. Corcept has licensed s...

Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?

IMMY is expected to come to market with a drug to treat dry eye, putting it in competition with Restasis. after it sold its Restasis patents to St. Regis Mohawk Tribe to protect them from an inter partes review by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board .

Pulmatrix Receives Key Patents on its Inhaled Drug Delivery Technology and its COPD Drug

LEXINGTON, Mass., Sept. 20, 2017 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two important new patents from the United States Patent and Trademark Office. The first new patent expands the potential of Pulmatrix's technology for...

AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

CAMBRIDGE, Mass., Sept. 20, 2017 /PRNewswire/ -- AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the Company's Ammonia Oxidizing Bacteria (AOB) for the treatment of acne. The lead candidate is c...

PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech

PureTech Health plc (“PureTech Health” or the “Company”, LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers program. The patent broadly covers methods of assessing a mental or physical con...

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 20, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical method...

DelMar Pharma Announces Issuance Of New Patent On First-In-Class DNA-Targeting Agent, VAL-083

  Life Sciences Jobs   ...

PureTech Notes U.S. Patent Issuance Broadly Covering Methods Of Assessing Mental And Physical Condition From Human Speech

  Life Sciences Jobs   ...

CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding

WOBURN, Mass., Dec. 19, 2012 /PRNewswire/ -- CutisPharma, Inc. today announced that the United States Patent and Trademark Office has issued a patent (US 8,276,757 B2) regarding a method for the preparation, storage and dispensing of compounded suppositories. The FIRST® container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy...

Biosafe Defenses LLC Announces a New Groundbreaking Disinfectant after 10 Years of Research

Biosafe Defenses LLC (formerly Biosafe Technologies LLC), the world leader in the creation of an entirely new class of light-activated disinfectants, antibacterials and biocides for the home, hospitals and industry, has just announced the receipt of a critical ninth US Patent, entitled “Conjugated Polyelectrolytes and Methods of Using the Same.” U.S. P...

STAT Plus: Pricing wars flare in Ireland as government battles with two drug makers

“Ireland seems to be the stage of some of the most bizarre pharmaceutical company behavior these days,” wrote a former director at Medicines Patent Pool.

MiMedx Group, Inc. Announces Release Date for 2013 Third Quarter Results

MARIETTA, Ga., Oct. 4, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the third quarter ended September 30, 2013, will be released before the opening of the market on Wednesday, October 30, 2013. ...

Mylan Attacks Allergan's 'Desperate' Measures To Protect Restasis

The Restasis patent battle between Mylan and Allergan is heating up. Mylan heavily criticized Allergan for partnering with St. Regis Mohawks to protect the patents, calling the arrangement "desperate": Mylan has had no shortage of critics over the last year as it suffered from a stinging EpiPen pricing scandal.

MiMedx Patent Infringement Lawsuit Updates

MARIETTA, Ga., Sept. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing proprietary human placental tissue allografts, announced today that the Company prevailed in its patent infringement lawsuit against Musculoskeletal Transplant Foundation, Inc. ("MTF"), Medline Industri...

Cardiosolutions, Inc. Key US Patent Application for Adjustable "Spacer" Technology to Treat Heart Valve Regurgitation Receives Notice of Allowance

WEST BRIDGEWATER, Mass., Sept. 18, 2017 /PRNewswire/ -- Cardiosolutions, Inc., today announced that the United States Patent and Trademark Office has issued a Notice of Allowance to grant a key US patent covering the company's proprietary 'spacer' technology for the treatment of regurgitation in incompetent heart valves. The allowed patent underlies the company's innovative Mitra-Spacer™ implant...

STAT Plus: Pharmalittle: Senator leans on Allergan over Mohawk deal; insurers limit access to pain meds

U.S. Sen. Sherrod Brown wants Allergan to explain its patent deal with the Mohawk tribe and ensure "this go-around (does not) become the new normal."

Can-Fite BioPharma Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

  Life Sciences Jobs   ...

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering Its Combination Therapy For Hard-To-Treat Cancers

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy Biological Patent market research data and corporate reports here